Company intelligence / Profile preview

Nail Genesis

Ownership: Private
Development stage: Preclinical

Overview

Nail Genesis is conducting a multicenter, randomized, double-blind clinical trial for its DLSO product to treat onychomycosis. The product has shown efficacy in feasibility studies.

Therapeutic areas: Infectious Diseases
Modalities: Topical polymer
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Nuvail

Commercial

Indications: Nail dystrophy, Nail splitting, Nail fragility

Beyond the preview

Go deeper on Nail Genesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nail Genesis.

Explore the full profile